RNA-Based Therapeutics and Vaccines Market Analysis and Forecast to 2034

Published Jul 22, 2025

Length 393 Pages

SKU # GIS20212795

Description

RNA-Based Therapeutics and Vaccines Market is anticipated to expand from $4.8 billion in 2024 to $25.3 billion by 2034, growing at a CAGR of approximately 18.1%. The RNA-Based Therapeutics and Vaccines Market represents a cutting-edge segment within the biomedical and pharmaceutical industries, characterized by its focus on RNA molecules as mechanisms for therapeutic interventions and preventative healthcare solutions. These biologics are designed to utilize the cellular machinery to produce therapeutic proteins or to modulate gene expression, offering potential treatments for a variety of diseases including genetic disorders, cancers, and infectious diseases. A significant driver of growth in this market is the rapid advancements in RNA technology, spurred largely by the successful deployment of mRNA COVID-19 vaccines. This success has not only propelled research and investment into mRNA vaccines for other infectious diseases but also accelerated the development of RNA-based therapies for chronic and genetic diseases. The versatility and rapid manufacturability of RNA are key advantages that are expected to fuel further innovation and adoption in the sector. In the therapeutic domain, RNA-based treatments such as siRNA and miRNA therapies are being developed to silence specific genes responsible for disease states, offering a new layer of precision in treatment modalities that were previously unachievable with traditional small molecule drugs. Meanwhile, in the vaccine sector, beyond infectious diseases, researchers are exploring mRNA vaccines for cancer, where the approach aims to train the immune system to target specific tumor antigens, heralding a new era in oncology. The promise of RNA-based therapeutics and vaccines is immense, with potential impacts spanning from dramatically improved patient outcomes to the creation of entirely new therapeutic categories. As scientific understanding and technological capabilities continue to advance, the RNA-Based Therapeutics and Vaccines Market is expected to experience robust growth and transformation, making it a pivotal area of interest for investors and healthcare providers alike.

Key Market Drivers

Drivers in the RNA-Based Therapeutics and Vaccines Market include: Innovative Therapeutic Potential: RNA-based therapies, including mRNA vaccines, offer groundbreaking potential in treating and preventing a wide range of diseases, from infectious diseases to cancer, by instructing cells to produce therapeutic proteins. Advancements in Delivery Mechanisms: Progress in nanoparticle encapsulation and other delivery technologies has significantly enhanced the stability and efficacy of RNA therapies, expanding their clinical application. COVID-19 Pandemic Response: The successful deployment of mRNA vaccines for COVID-19 has dramatically accelerated interest and investment in RNA technology, highlighting its rapid scalability and adaptability to emerging health threats. Regulatory Support and Funding: Increased support from regulatory bodies and substantial funding for research and development are driving rapid advancements and approvals in the RNA therapeutics sector. Growing Partnerships and Collaborations: Strategic alliances between biotech firms and pharmaceutical giants are crucial in overcoming production and distribution challenges, facilitating global access to RNA-based therapies and vaccines.

Key Restraints and Challenges

Key Market Restraints for the RNA-Based Therapeutics and Vaccines Market: Regulatory and Safety Challenges: Stringent regulatory policies and the high bar for safety profiles pose significant challenges in the development and approval of RNA-based therapies and vaccines. Technical Hurdles in Delivery Systems: The delivery of RNA molecules into target cells without degradation or eliciting unintended immune responses remains a critical obstacle, limiting therapeutic efficacy. High Development Costs: The research, development, and manufacturing processes for RNA-based therapeutics are complex and expensive, restricting entry and scaling opportunities for smaller players. Storage and Stability Issues: RNA molecules typically require ultra-cold storage conditions to maintain stability, which complicates logistics and distribution, particularly in low-resource settings. Market Competition from Established Therapeutics: The presence of existing and more traditional therapies that are already well integrated into healthcare systems can hinder the adoption and market penetration of newer RNA-based treatments.

Key Players

Bio NTech, Moderna, Cure Vac, Arcturus Therapeutics, Translate Bio, Sangamo Therapeutics, Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Dicerna Pharmaceuticals, Arrowhead Pharmaceuticals, Silence Therapeutics, Pro QR Therapeutics, Arbutus Biopharma, Marina Biotech, Benitec Biopharma, Regulus Therapeutics, Intellia Therapeutics, Beam Therapeutics, Editas Medicine

Research Scope:

Estimates and forecasts the overall market size across type, application, and region.
Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

What to expect in the report:

Assess and project the market size for the Adaptive Reuse Architecture sector, segmented by type, application, and geography

Provide detailed insights and essential takeaways on qualitative and quantitative trends, market dynamics, structural framework, competitive landscape, and company profiling
Identify key factors driving market growth, alongside challenges, opportunities, drivers, and restraints
Determine elements that may constrain company involvement in international markets, aiding in the calibration of market share expectations and growth rates
Track and evaluate strategic developments such as acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities
Conduct a strategic analysis of smaller market segments, emphasizing their potential, unique growth patterns, and impact on the broader market
Elucidate the competitive landscape, including an evaluation of business and corporate strategies, to monitor and analyze competitive progressions
Identify leading market participants based on business objectives, geographic presence, product offerings, and strategic initiatives

Chapter : 1: Sections : 1.1 Market Definition; 1.2 Market Segmentation; 1.3 Regional Coverage; 1.4 Key Company Profiles; 1.5 Key Manufacturers Profiles; 1.6 Data Snapshot : Executive Summary
Chapter : 2: Sections : 2.1 Summary; 2.2 Key Opinion Leaders; 2.3 Key Highlights of the Market, by Type; 2.4 Key Highlights of the Market, by Product; 2.5 Key Highlights of the Market, by Technology; 2.6 Key Highlights of the Market, by Application; 2.7 Key Highlights of the Market, by End user; 2.8 Key Highlights of the Market, by Component; 2.9 Key Highlights of the Market, by Stage; 2.10 Key Highlights of the Market, by Services; 2.11 Key Highlights of the Market, by Mode; 2.12 Key Highlights of the Market, by North America; 2.13 Key Highlights of the Market, by Europe; 2.14 Key Highlights of the Market, by Asia-Pacific; 2.15 Key Highlights of the Market, by Latin America; 2.16 Key Highlights of the Market, by Middle East; 2.17 Key Highlights of the Market, by Africa : Premium Insights on the Market
Chapter : 3: Sections : 3.1 Market Attractiveness Analysis, by Region; 3.2 Market Attractiveness Analysis, by Type; 3.3 Market Attractiveness Analysis, by Product; 3.4 Market Attractiveness Analysis, by Technology; 3.5 Market Attractiveness Analysis, by Application; 3.6 Market Attractiveness Analysis, by End user; 3.7 Market Attractiveness Analysis, by Component; 3.8 Market Attractiveness Analysis, by Stage; 3.9 Market Attractiveness Analysis, by Services; 3.10 Market Attractiveness Analysis, by Mode; 3.11 Market Attractiveness Analysis, by North America; 3.12 Market Attractiveness Analysis, by Europe; 3.13 Market Attractiveness Analysis, by Asia-Pacific; 3.14 Market Attractiveness Analysis, by Latin America; 3.15 Market Attractiveness Analysis, by Middle East; 3.16 Market Attractiveness Analysis, by Africa : Market Analysis
Chapter : 4: Sections : 4.1 Market Drivers; 4.2 Market Trends; 4.3 Market Restraints; 4.4 Market Opportunities; 4.5 Porters Five Forces Analysis; 4.6 PESTLE Analysis; 4.7 Value Chain Analysis; 4.8 4Ps Model; 4.9 ANSOFF Matrix : Market Strategy
Chapter : 5: Sections : 5.1 Parent Market Analysis; 5.2 Supply-Demand Analysis; 5.3 Consumer Buying Interest; 5.4 Case Study Analysis; 5.5 Pricing Analysis; 5.6 Regulatory Landscape; 5.7 Supply Chain Analysis; 5.8 Competition Product Analysis; 5.9 Recent Developments : Market Size
Chapter : 6: Sections : 6.1 RNA-Based Therapeutics and Vaccines Market Market Size, by Value; 6.2 RNA-Based Therapeutics and Vaccines Market Market Size, by Volume : RNA-Based Therapeutics and Vaccines Market Market, by Type
Chapter : 7: Sections : 7.1 Key Market Overview, Trends & Opportunity Analysis; 7.2 Market Size and Forecast, by Type; 7.2.1 Market Size and Forecast, by mRNA-Based Therapeutics; 7.2.1 Market Size and Forecast, by siRNA-Based Therapeutics; 7.2.1 Market Size and Forecast, by miRNA-Based Therapeutics; 7.2.1 Market Size and Forecast, by shRNA-Based Therapeutics; 7.2.1 Market Size and Forecast, by RNA Interference; 7.2.1 Market Size and Forecast, by RNA Aptamers; 7.2.1 Market Size and Forecast, by RNA Vaccines; 7.2.1 Market Size and Forecast, by Antisense RNA; 7.3 Market Size and Forecast, by Product; 7.3.1 Market Size and Forecast, by RNA-Based Drugs; 7.3.1 Market Size and Forecast, by RNA-Based Vaccines; 7.3.1 Market Size and Forecast, by RNA-Based Diagnostics; 7.4 Market Size and Forecast, by Technology; 7.4.1 Market Size and Forecast, by Lipid Nanoparticles; 7.4.1 Market Size and Forecast, by RNA Delivery Platforms; 7.4.1 Market Size and Forecast, by CRISPR Technology; 7.4.1 Market Size and Forecast, by RNA Sequencing; 7.4.1 Market Size and Forecast, by RNA Synthesis; 7.5 Market Size and Forecast, by Application; 7.5.1 Market Size and Forecast, by Oncology; 7.5.1 Market Size and Forecast, by Infectious Diseases; 7.5.1 Market Size and Forecast, by Cardiovascular Diseases; 7.5.1 Market Size and Forecast, by Genetic Disorders; 7.5.1 Market Size and Forecast, by Metabolic Disorders; 7.5.1 Market Size and Forecast, by Neurological Disorders; 7.5.1 Market Size and Forecast, by Rare Diseases; 7.6 Market Size and Forecast, by End user; 7.6.1 Market Size and Forecast, by Pharmaceutical Companies; 7.6.1 Market Size and Forecast, by Biotechnology Companies; 7.6.1 Market Size and Forecast, by Academic Research Institutes; 7.6.1 Market Size and Forecast, by Contract Research Organizations; 7.7 Market Size and Forecast, by Component; 7.7.1 Market Size and Forecast, by RNA Molecules; 7.7.1 Market Size and Forecast, by Delivery Systems; 7.7.1 Market Size and Forecast, by Formulation Components; 7.8 Market Size and Forecast, by Stage; 7.8.1 Market Size and Forecast, by Discovery; 7.8.1 Market Size and Forecast, by Preclinical; 7.8.1 Market Size and Forecast, by Clinical Trials; 7.8.1 Market Size and Forecast, by Commercialization; 7.9 Market Size and Forecast, by Services; 7.9.1 Market Size and Forecast, by Custom Synthesis; 7.9.1 Market Size and Forecast, by Analytical Services; 7.9.1 Market Size and Forecast, by Consulting Services; 7.9.1 Market Size and Forecast, by Regulatory Services; 7.10 Market Size and Forecast, by Mode; 7.10.1 Market Size and Forecast, by In Vivo; 7.10.1 Market Size and Forecast, by In Vitro; 7.10.1 Market Size and Forecast, by Ex Vivo : RNA-Based Therapeutics and Vaccines Market Market, by Region
Chapter : 8: Sections : 8.1 Overview; 8.2 North America; 8.3.1 Key Market Trends and Opportunities; 8.3.2 North America Market Size and Forecast, by Type; 8.3.3 North America Market Size and Forecast, by mRNA-Based Therapeutics; 8.3.4 North America Market Size and Forecast, by siRNA-Based Therapeutics; 8.3.5 North America Market Size and Forecast, by miRNA-Based Therapeutics; 8.3.6 North America Market Size and Forecast, by shRNA-Based Therapeutics; 8.3.7 North America Market Size and Forecast, by RNA Interference; 8.3.8 North America Market Size and Forecast, by RNA Aptamers; 8.3.9 North America Market Size and Forecast, by RNA Vaccines; 8.3.10 North America Market Size and Forecast, by Antisense RNA; 8.3.11 North America Market Size and Forecast, by Product; 8.3.12 North America Market Size and Forecast, by RNA-Based Drugs; 8.3.13 North America Market Size and Forecast, by RNA-Based Vaccines; 8.3.14 North America Market Size and Forecast, by RNA-Based Diagnostics; 8.3.15 North America Market Size and Forecast, by Technology; 8.3.16 North America Market Size and Forecast, by Lipid Nanoparticles; 8.3.17 North America Market Size and Forecast, by RNA Delivery Platforms; 8.3.18 North America Market Size and Forecast, by CRISPR Technology; 8.3.19 North America Market Size and Forecast, by RNA Sequencing; 8.3.20 North America Market Size and Forecast, by RNA Synthesis; 8.3.21 North America Market Size and Forecast, by Application; 8.3.22 North America Market Size and Forecast, by Oncology; 8.3.23 North America Market Size and Forecast, by Infectious Diseases; 8.3.24 North America Market Size and Forecast, by Cardiovascular Diseases; 8.3.25 North America Market Size and Forecast, by Genetic Disorders; 8.3.26 North America Market Size and Forecast, by Metabolic Disorders; 8.3.27 North America Market Size and Forecast, by Neurological Disorders; 8.3.28 North America Market Size and Forecast, by Rare Diseases; 8.3.29 North America Market Size and Forecast, by End user; 8.3.30 North America Market Size and Forecast, by Pharmaceutical Companies; 8.3.31 North America Market Size and Forecast, by Biotechnology Companies; 8.3.32 North America Market Size and Forecast, by Academic Research Institutes; 8.3.33 North America Market Size and Forecast, by Contract Research Organizations; 8.3.34 North America Market Size and Forecast, by Component; 8.3.35 North America Market Size and Forecast, by RNA Molecules; 8.3.36 North America Market Size and Forecast, by Delivery Systems; 8.3.37 North America Market Size and Forecast, by Formulation Components; 8.3.38 North America Market Size and Forecast, by Stage; 8.3.39 North America Market Size and Forecast, by Discovery; 8.3.40 North America Market Size and Forecast, by Preclinical; 8.3.41 North America Market Size and Forecast, by Clinical Trials; 8.3.42 North America Market Size and Forecast, by Commercialization; 8.3.43 North America Market Size and Forecast, by Services; 8.3.44 North America Market Size and Forecast, by Custom Synthesis; 8.3.45 North America Market Size and Forecast, by Analytical Services; 8.3.46 North America Market Size and Forecast, by Consulting Services; 8.3.47 North America Market Size and Forecast, by Regulatory Services; 8.3.48 North America Market Size and Forecast, by Mode; 8.3.49 North America Market Size and Forecast, by In Vivo; 8.3.50 North America Market Size and Forecast, by In Vitro; 8.3.51 North America Market Size and Forecast, by Ex Vivo; 8.3.52 United States; 8.3.53 United States Market Size and Forecast, by Type; 8.3.54 United States Market Size and Forecast, by mRNA-Based Therapeutics; 8.3.55 United States Market Size and Forecast, by siRNA-Based Therapeutics; 8.3.56 United States Market Size and Forecast, by miRNA-Based Therapeutics; 8.3.57 United States Market Size and Forecast, by shRNA-Based Therapeutics; 8.3.58 United States Market Size and Forecast, by RNA Interference; 8.3.59 United States Market Size and Forecast, by RNA Aptamers; 8.3.60 United States Market Size and Forecast, by RNA Vaccines; 8.3.61 United States Market Size and Forecast, by Antisense RNA; 8.3.62 United States Market Size and Forecast, by Product; 8.3.63 United States Market Size and Forecast, by RNA-Based Drugs; 8.3.64 United States Market Size and Forecast, by RNA-Based Vaccines; 8.3.65 United States Market Size and Forecast, by RNA-Based Diagnostics; 8.3.66 United States Market Size and Forecast, by Technology; 8.3.67 United States Market Size and Forecast, by Lipid Nanoparticles; 8.3.68 United States Market Size and Forecast, by RNA Delivery Platforms; 8.3.69 United States Market Size and Forecast, by CRISPR Technology; 8.3.70 United States Market Size and Forecast, by RNA Sequencing; 8.3.71 United States Market Size and Forecast, by RNA Synthesis; 8.3.72 United States Market Size and Forecast, by Application; 8.3.73 United States Market Size and Forecast, by Oncology; 8.3.74 United States Market Size and Forecast, by Infectious Diseases; 8.3.75 United States Market Size and Forecast, by Cardiovascular Diseases; 8.3.76 United States Market Size and Forecast, by Genetic Disorders; 8.3.77 United States Market Size and Forecast, by Metabolic Disorders; 8.3.78 United States Market Size and Forecast, by Neurological Disorders; 8.3.79 United States Market Size and Forecast, by Rare Diseases; 8.3.80 United States Market Size and Forecast, by End user; 8.3.81 United States Market Size and Forecast, by Pharmaceutical Companies; 8.3.82 United States Market Size and Forecast, by Biotechnology Companies; 8.3.83 United States Market Size and Forecast, by Academic Research Institutes; 8.3.84 United States Market Size and Forecast, by Contract Research Organizations; 8.3.85 United States Market Size and Forecast, by Component; 8.3.86 United States Market Size and Forecast, by RNA Molecules; 8.3.87 United States Market Size and Forecast, by Delivery Systems; 8.3.88 United States Market Size and Forecast, by Formulation Components; 8.3.89 United States Market Size and Forecast, by Stage; 8.3.90 United States Market Size and Forecast, by Discovery; 8.3.91 United States Market Size and Forecast, by Preclinical; 8.3.92 United States Market Size and Forecast, by Clinical Trials; 8.3.93 United States Market Size and Forecast, by Commercialization; 8.3.94 United States Market Size and Forecast, by Services; 8.3.95 United States Market Size and Forecast, by Custom Synthesis; 8.3.96 United States Market Size and Forecast, by Analytical Services; 8.3.97 United States Market Size and Forecast, by Consulting Services; 8.3.98 United States Market Size and Forecast, by Regulatory Services; 8.3.99 United States Market Size and Forecast, by Mode; 8.3.100 United States Market Size and Forecast, by In Vivo; 8.3.101 United States Market Size and Forecast, by In Vitro; 8.3.102 United States Market Size and Forecast, by Ex Vivo; 8.3.103 Local Competition Analysis; 8.3.104 Local Market Analysis : Competitive Landscape
Chapter : 9: Sections : 9.1 Overview; 9.2 Market Share Analysis; 9.3 Key Player Positioning; 9.4 Competitive Leadership Mapping; 9.5 Star Players; 9.6 Innovators; 9.7 Emerging Players; 9.8 Vendor Benchmarking; 9.9 Developmental Strategy Benchmarking; 9.10 New Product Developments; 9.11 Product Launches; 9.12 Business Expansions; 9.13 Partnerships, Joint Ventures, and Collaborations; 9.14 Mergers and Acquisitions : Company Profiles - Overview, Segments, Performance, Products, Key Strategies, SWOT Analysis
Chapter : 10: Sections : 10.1 Bio NTech; 10.2 Moderna; 10.3 Cure Vac; 10.4 Arcturus Therapeutics; 10.5 Translate Bio; 10.6 Sangamo Therapeutics; 10.7 Sarepta Therapeutics; 10.8 Ionis Pharmaceuticals; 10.9 Alnylam Pharmaceuticals; 10.10 Dicerna Pharmaceuticals; 10.11 Arrowhead Pharmaceuticals; 10.12 Silence Therapeutics; 10.13 Pro QR Therapeutics; 10.14 Arbutus Biopharma; 10.15 Marina Biotech; 10.16 Benitec Biopharma; 10.17 Regulus Therapeutics; 10.18 Intellia Therapeutics; 10.19 Beam Therapeutics; 10.20 Editas Medicine; 10.21

Pricing

Currency Rates

Single User Email from Publisher $4,750
Global Site License Email from Publisher $6,750

How Do Licenses Work?

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

Chat Now